Nu Skin Enterprises, Inc. filings document the company’s operating results, governance, executive leadership changes and financing arrangements. Recent 8-K reports include quarterly and annual financial-result releases, officer appointments and resignations, compensation arrangements, and material definitive agreements tied to amended credit facilities.
The company’s proxy materials provide annual meeting governance and executive-compensation disclosures, including board and compensation matters reported under Schedule 14A. Nu Skin’s regulatory record also reflects its capital structure and liquidity arrangements, including term loan and revolving credit facilities, alongside formal disclosures for its beauty and wellness operations, affiliate platform and Rhyz-related business activities.
Nu Skin Enterprises reported Q1 2026 revenue of $320.6 million, down 12.0% year over year, with a modest +1.1% foreign-exchange benefit. GAAP diluted EPS was $0.04, or $0.14 excluding inventory write-offs, other charges and impairment, compared with $2.14 or $0.23 on an adjusted basis a year ago when results included a large gain from the Mavely sale.
Customers fell 14% to 669,535, Paid Affiliates declined 8% to 120,850, and Sales Leaders decreased 13% to 26,915. Adjusted operating margin was 3.6% versus 6.4% last year. The company returned $2.9 million via dividends and $5.0 million through share repurchases.
For Q2 2026, Nu Skin guides revenue to $330–$360 million with EPS of $0.15–$0.25. Full-year 2026 revenue is projected at $1.35–$1.50 billion and EPS of $0.70–$1.10, or $0.80–$1.20 excluding specified charges, as it invests behind its Prysm iO wellness platform and emerging-market expansion.
Nu Skin Enterprises is asking stockholders to vote at its May 28, 2026 annual meeting on four items: electing nine directors, an advisory vote on executive pay, approving an amended and restated 2024 Omnibus Incentive Plan, and ratifying PricewaterhouseCoopers LLP as auditor for 2026.
The company highlights strong governance practices, including a mostly independent board, separate Chair and CEO roles, a lead independent director, annual board/committee evaluations, and robust risk, cybersecurity and sustainability oversight. Executive pay is heavily performance-based: 2025 cash incentives paid at 21.9% of target after financial metrics came in below minimum levels, while some performance stock units paid out partly or not at all.
In 2025, Nu Skin generated $1.49 billion in revenue with core Nu Skin gross margin of 77.4%, and completed a $250 million sale of its Mavely business, using proceeds to reduce debt and fund innovation. CEO Ryan Napierski’s 2025 compensation was $5.97 million, largely in equity, and 97% of votes supported the prior say-on-pay proposal, which the board views as endorsement of its pay-for-performance design.
NU SKIN ENTERPRISES, INC. Chief Financial Officer Chelsea K. Lantz filed an initial Form 3 reporting her beneficial ownership in the company. The filing shows direct holdings of 42,100 shares of Class A Common Stock, establishing her reported equity position as an executive officer.
Nu Skin Enterprises entered into a new Second Amended and Restated Credit Agreement on March 27, 2026, establishing a $175 million term loan and a $75 million revolving credit facility, each with a five-year term. The term loan was fully drawn at closing and used to repay all amounts outstanding under the prior credit agreement, effectively refinancing the company’s main bank debt.
The revolving facility includes up to $10 million for swingline loans and up to $10 million for letters of credit. Loans bear interest at Term SOFR plus a spread starting at 1.75% or at a base rate plus a spread starting at 0.75%, with both spreads adjustable based on Nu Skin’s consolidated leverage ratio.
The facilities are guaranteed by certain material domestic subsidiaries and secured by liens on the capital stock of material subsidiaries. Key financial covenants require a consolidated leverage ratio not exceeding 2.25 to 1.00 and an interest coverage ratio of at least 3.00 to 1.00, alongside customary restrictions on additional debt, liens, dividends, acquisitions and asset sales.
Nu Skin Enterprises Inc: The Vanguard Group reports it beneficially owns 0 shares (0%) of Nu Skin common stock following an internal realignment. The filing states certain Vanguard subsidiaries now report separately in reliance on SEC Release No. 34-39538 (January 12, 1998), and Vanguard no longer is deemed to beneficially own securities held by those subsidiaries. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Nu Skin Enterprises announced that Executive Vice President and Chief Financial Officer James D. Thomas resigned on March 17, 2026 to pursue an outside opportunity. On March 18, 2026, the board appointed Vice President and Corporate Controller Chelsea K. Lantz as Interim CFO while a search for a permanent CFO, including internal and external candidates, is conducted.
Lantz, age 42, has been with Nu Skin since 2011 in various finance and audit roles and became Corporate Controller in 2023. As Interim CFO she will receive a $300,000 annual salary, a target incentive bonus equal to 35% of salary, and a $25,000 stipend for each quarter she serves in the interim role. The company states there are no family relationships or related-person transactions involving her and expects to enter into a standard indemnification agreement. A press release dated March 20, 2026 announces her appointment and highlights her role in cost-improvement efforts that contributed to a significant year-over-year EPS increase.
NU SKIN ENTERPRISES director Edwina D. Woodbury acquired additional shares through a plan-related dividend reinvestment. On 2026-03-11, she received 14 shares of Class A Common Stock at $7.31 per share under the company’s Deferred Compensation Plan. Following this automatic, non-open-market transaction, she directly holds 42,993 shares.
Keisel Justin S reported acquisition or exercise transactions in this Form 4 filing.
NU SKIN ENTERPRISES, INC. executive Justin S. Keisel, EVP and President of Global Sales, received a grant of 47,059 shares of Class A Common Stock. The award was recorded at a price of $0.00 per share, indicating an equity grant rather than an open-market purchase. Following this grant, Keisel directly holds 160,170 shares of Nu Skin Class A Common Stock.
Nu Skin Enterprises Chief Product Officer Steven Keith Hatchett reported an equity award of 77,941 shares of Class A common stock on March 6, 2026. The shares were acquired as a grant with a reported price of $0.00 per share, indicating a non-cash award. Following this grant, Hatchett's directly held ownership increased to 260,818 shares of Nu Skin Class A common stock.